WO2009096481A1 - 皮膚外用組成物および美白化粧料 - Google Patents
皮膚外用組成物および美白化粧料 Download PDFInfo
- Publication number
- WO2009096481A1 WO2009096481A1 PCT/JP2009/051488 JP2009051488W WO2009096481A1 WO 2009096481 A1 WO2009096481 A1 WO 2009096481A1 JP 2009051488 W JP2009051488 W JP 2009051488W WO 2009096481 A1 WO2009096481 A1 WO 2009096481A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- composition
- hydroquinone
- weight
- liquid crystal
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Definitions
- the present invention relates to a composition for external use on skin having an excellent whitening action and reduced side effects.
- hydroquinone is useful as a component having a whitening effect in medicine and beauty (see Patent Document 1 if necessary).
- its concentration is usually set to 4% by weight or more in order to make the whitening effect more certain.
- hydroquinone is highly irritating to the skin, some people may develop allergic symptoms if an external preparation containing hydroquinone at such a concentration is applied. Therefore, while reducing the side effect of hydroquinone in external preparations while reducing side effects, there is a demand for a method that allows hydroquinone to effectively exert a whitening effect at a lower concentration. At present, no effective means has been found because it is likely to cause a decrease in action, manifestation of cytotoxicity, discoloration, and the like. Japanese Patent No. 3712066
- an object of the present invention is to provide a composition for external use of skin having hydroquinone as an active ingredient, which has an excellent whitening action and has reduced side effects.
- the present inventor can incorporate the hydroquinone into the lyotropic liquid crystal so that the component can be efficiently percutaneously taken into the living body, and the hydroquinone It has been found that deterioration due to oxidation is suppressed, and as a result, the component can effectively exert a whitening effect at a lower concentration.
- composition for external use of the skin of the present invention based on the above findings is characterized in that hydroquinone or a derivative thereof is blended with lyotropic liquid crystal as described in claim 1.
- the whitening cosmetic composition of the present invention comprises the composition for external use of the skin according to claim 1 as described in claim 2.
- the combination cosmetic of the present invention comprises the external composition for skin according to claim 1 and the external composition for skin containing retinoid, which are separately packaged and used in combination. It is characterized by that.
- the combination cosmetic according to claim 4 is the combination cosmetic according to claim 3, wherein the external composition for skin containing retinoid contains the retinoid in a form encapsulated in divalent metal inorganic salt fine particles.
- compositions for external use with hydroquinone as an active ingredient which has an excellent whitening action and has reduced side effects.
- hydroquinone or a derivative thereof is used as an active ingredient of the whitening cosmetic.
- hydroquinone derivative include arbutin, which is known to have a whitening effect as in the case of hydroquinone.
- a lyotropic liquid crystal is a mixture of a surfactant (an amphiphilic molecule having a hydrophilic part and a hydrophobic (lipophilic) part in the molecule) and water in a coexisting system. It means a liquid crystal state (a state having a fluidity like a liquid while maintaining a certain regularity in its molecular arrangement like a crystal) depending on the ratio and temperature.
- the lyotropic liquid crystal can be prepared by mixing a surfactant and water as constituent components thereof at a predetermined ratio at a predetermined temperature. If necessary, an operation of temporarily heating the constituent components before mixing or after mixing may be performed.
- Surfactant which is a constituent of lyotropic liquid crystal, can form a liquid crystal state (especially, a periodic structure with a surface interval of 10 nm to 800 nm) depending on the mixing ratio with water and temperature in a coexisting system with water. If it is, it will not be restrict
- Anionic surfactants include soap (fatty acid sodium and potassium salts), alkylbenzene sulfonate (sodium salt, etc.), higher alcohol sulfate (sodium salt), polyoxyethylene alkyl ether sulfate (sodium) Salts), ⁇ -sulfo fatty acid esters, ⁇ -olefin sulfonates (such as sodium salts), monoalkyl phosphate esters (such as sodium salts), alkane sulfonates (such as sodium salts), and the like.
- Examples of the cationic surfactant include alkyltrimethylammonium salts (such as chloride), dialkyldimethylammonium salts (such as chloride), alkyldimethylbenzylammonium salts (such as chloride), and amine salts (such as acetate and hydrochloride).
- Examples of amphoteric surfactants include alkylamino fatty acid salts (such as sodium salts), alkylbetaines, and alkylamine oxides.
- the proportion of the surfactant in the lyotropic liquid crystal is preferably 5% by weight to 80% by weight, more preferably 7% by weight to 70% by weight, and further preferably 10% by weight to 65% by weight.
- purified water can be used as the water that is a constituent of the lyotropic liquid crystal.
- the water may contain a polar organic solvent such as ethanol or isopropanol that is compatible with water.
- the proportion of water in the lyotropic liquid crystal is preferably 5% by weight to 80% by weight, more preferably 10% by weight to 60% by weight, and further preferably 13% by weight to 50% by weight.
- a single polyhydric alcohol may be used alone, or a plurality of types may be mixed and used.
- the proportion of polyhydric alcohol in the lyotropic liquid crystal is preferably 1% to 55% by weight, more preferably 3% to 52% by weight, and further preferably 5% to 50% by weight.
- composition for external use of the skin of the present invention can be produced, for example, by adding hydroquinone or a derivative thereof as it is or dissolved in an appropriate solvent (such as water) after preparing or preparing the lyotropic liquid crystal, and dissolving it in the liquid crystal. Can be done.
- the content of hydroquinone or a derivative thereof in the external composition for skin of the present invention is preferably 0.01% by weight to 3% by weight, more preferably 0.05% by weight to 1.5% by weight.
- the compounding amount may be small because it has an effect of suppressing deterioration due to oxidation of the metal, for example, 0.01 wt% to 0.3 wt% is desirable, and 0.03 wt% to 0.2 wt% is more desirable) , Preservatives such as methyl paraoxybenzoate and propyl paraoxybenzoate, thickeners such as cetanol, moisturizers such as glycosyl trehalose (for example, trade name: Tornare of Hayashibara Biochemical Laboratories), decamethylcyclopentasiloxane, etc. Feel improver, vitamin C derivatives such as ascorbyl tetrahexyl decanoate, etc. It may be contained.
- Preservatives such as methyl paraoxybenzoate and propyl paraoxybenzoate
- thickeners such as cetanol
- moisturizers such as glycosyl trehalose (for example, trade name: Tornare of Hayashibara Biochemical Laboratories),
- Manufacture example 1 Manufacture of the composition for external use of skin of this invention The lyotropic liquid crystal which consists of three types of prescription shown in following Table 1 was prepared.
- Test Example 1 Preventive effect of whitening action (test method) The back of a colored guinea pig (Weiser Maples, 5 weeks old, male) with melanin pigment-producing cells is shaved, and the shaved portion is washed with lukewarm water, then UV-A for 5 hours and UV-B for 1 hour. After irradiation for 30 minutes, 30 mg of the external composition for skin of the present invention (formulation 2: 1% by weight hydroquinone-containing composition) of the present invention was applied to an area of 2 cm ⁇ 2 cm in the part.
- formulation 2 1% by weight hydroquinone-containing composition
- Test Example 2 Therapeutic effect of whitening action (test method) The back of a colored guinea pig with melanin-producing cells (Weiser Maples, 12 weeks old, male) is shaved, the shaved part is washed with lukewarm water, UV-A for 5 hours and UV-B for 1 hour. A pattern for irradiation for 1 minute was repeated once a day for a total of 16 times to prepare a spot model. 30 mg of the sample was applied to the 2 cm ⁇ 2 cm area of the stain area once a day, and after 5 times in total, the lightness of the skin where the sample was applied was measured with a color difference meter (Minolta: Color Reader CR400).
- aqueous solution containing 1% by weight of hydroquinone (containing 0.05% by weight of sodium pyrosulfite and 1% by weight of methyl parahydroxybenzoate as other components).
- hydroquinone containing 0.05% by weight of sodium pyrosulfite and 1% by weight of methyl parahydroxybenzoate as other components.
- the aqueous solution containing 1% by weight of hydroquinone showed no discoloration when stored at room temperature, but noticeable discoloration when stored at 40 ° C.
- the composition for external use of the present invention showed no discoloration not only when stored at room temperature but also when stored at 40 ° C.
- the present invention has industrial applicability in that it can provide an external skin composition containing hydroquinone as an active ingredient, which has an excellent whitening action and reduced side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
また、本発明の美白化粧料は、請求項2記載の通り、請求項1記載の皮膚外用組成物からなることを特徴とする。
また、本発明の組み合わせ化粧料は、請求項3記載の通り、請求項1記載の皮膚外用組成物とレチノイドを含有する皮膚外用組成物が各別包装されてなり、両者が組み合わせて使用されることを特徴とする。
また、請求項4記載の組み合わせ化粧料は、請求項3記載の組み合わせ化粧料において、レチノイドを含有する皮膚外用組成物がレチノイドを2価金属無機塩微粒子に封入された形態で含有することを特徴とする。
下記の表1に示す3種類の処方からなるリオトロピック液晶を調製した。
(試験方法)
メラニン色素産生細胞を持つ有色モルモット(Weiser Maples,5週齢,雄)の背部を毛剃りし、毛剃りした部分をぬるま湯で洗浄後、当該部分にUV-Aを5時間とUV-Bを1分間照射してから、当該部分内の2cm×2cmの面積に本発明の皮膚外用組成物(処方2:ハイドロキノン1重量%含有組成物)を30mg塗布した。この操作を1日1回で計9回繰り返し、実験開始前と実験終了後の本発明の皮膚外用組成物を塗布した部分の皮膚の明度を色彩色差計(ミノルタ社製:Color Reader CR400)で測定し、明度の変化(L値の変化量)を調べた。結果を表2と図1に示す。また、実験終了後の本発明の皮膚外用組成物を塗布した部分の皮膚を採取し、ホルマリンで固定した後、パラフィン包埋し、メラニン色素を黒く染め出すフォンタナマッソン法で染色してから断面写真を撮影した。結果を図2に示す。なお、表2と図1と図2には、ハイドロキノン4重量%配合市販品(クリーム剤、以下同じ)を塗布した場合についての結果(比較例)と処置を行わなかった場合の結果(コントロール)をあわせて示す。
表2と図1と図2から明らかなように、本発明の皮膚外用組成物のハイドロキノン含量は市販品のハイドロキノン含量の1/4であるにもかかわらず、市販品よりも優れた美白作用(予防的効果)を有することがわかった。
(試験方法)
メラニン色素産生細胞を持つ有色モルモット(Weiser Maples,12週齢,雄)の背部を毛剃りし、毛剃りした部分をぬるま湯で洗浄後、当該部分にUV-Aを5時間とUV-Bを1分間照射するパターンを1日1回で計16回繰り返し、シミモデルを作製した。シミ領域の2cm×2cmの面積にサンプルを1日1回30mg塗布し、計5回塗布後、サンプルを塗布した部分の皮膚の明度を色彩色差計(ミノルタ社製:Color Reader CR400)で測定し、シミ作製時点での明度からの変化(L値の変化量)を調べた。結果を表3と図3に示す。また、サンプルを塗布した部分の皮膚を採取し、ホルマリンで固定した後、パラフィン包埋し、メラニン色素を黒く染め出すフォンタナマッソン法で染色してから断面写真を撮影した。結果を図4に示す。なお、表3と図3と図4には、処置を行わなかった場合の結果(コントロール)をあわせて示す。サンプルは次の7種類とした(3、4、7については各組成物を15mgずつ塗布)。
(1)本発明の皮膚外用組成物(処方1:ハイドロキノン0.1重量%含有組成物)
(2)本発明の皮膚外用組成物(処方2:ハイドロキノン1重量%含有組成物)
(3)本発明の皮膚外用組成物(処方1のハイドロキノン0.1重量%含有組成物と、レチノイン酸(全トランス体)が封入された直径が10nm~1000nmの炭酸カルシウム微粒子(必要であれば国際公開第02/096396号パンフレットを参照のこと)をクリーム基材(成分:ステアレス-2、ステアレス-21、トリ(カプリリル/カプリン酸)グリセリル、オリーブスクアラン、ベヘニルアルコール、ジメチコン、BHT、パラオキシ安息香酸プロピル、リノールアミドプロピルPGジモニウムクロリドン酸、グリセリン、ヘキサンジオール、パラオキシ安息香酸メチル、ヒドロキシプロピルデンプンリン酸、水)に配合して得た組成物(レチノイン酸0.01重量%含量組成物)との併用
(4)本発明の皮膚外用組成物(処方1のハイドロキノン0.1重量%含有組成物と、レチノイン酸(全トランス体)が封入された直径が10nm~1000nmの炭酸カルシウム微粒子(同上)をクリーム基材(同上)に配合して得た組成物(レチノイン酸0.05重量%含量組成物)との併用
(5)ハイドロキノン4重量%配合市販品
(6)レチノイン酸(全トランス体)0.05重量%配合市販品
(7)ハイドロキノン4重量%配合市販品とレチノイン酸(全トランス体)0.05重量%配合市販品との併用
表3と図3と図4から明らかなように、サンプルNo.1の本発明の皮膚外用組成物のハイドロキノン含量はサンプルNo.5の市販品のハイドロキノン含量の1/40であるにもかかわらず、市販品よりも優れた美白作用(治療的効果)を有し、この作用はレチノイドを含有する皮膚外用組成物と組み合わせることでさらに向上することがわかった(サンプルNo.3およびサンプルNo.4)。
酸化防止剤であるピロ亜硫酸ナトリウムの含量が0.05重量%である本発明の皮膚外用組成物(処方3:ハイドロキノン1重量%含有組成物)を透明のガラス瓶に充填した後、キャップを閉め、全体をアルミ箔で包んで室温または40℃で1ヶ月保管した後の組成物の変色(褐変)の程度を目視で評価することで、ハイドロキノンの酸化による劣化の程度を評価した。また、ハイドロキノン1重量%含有水溶液(その他の成分としてピロ亜硫酸ナトリウム0.05重量%とパラオキシ安息香酸メチル1重量%を含有)についても同様の評価を行った。その結果、ハイドロキノン1重量%含有水溶液は、室温保管の場合には変色が認められなかったが、40℃保管の場合には顕著な変色が認められた。一方、本発明の皮膚外用組成物は、室温保管の場合のみならず40℃保管の場合にも変色は認められなかった。このことから、ハイドロキノンをリオトロピック液晶に配合することで、リオトロピック液晶がハイドロキノンの安定化に寄与し、ピロ亜硫酸ナトリウムの含量が0.05重量%とわずかであっても、ハイドロキノンの酸化による劣化を効果的に抑制できることがわかった。
ピロ亜硫酸ナトリウムの含量が0.1重量%である本発明の皮膚外用組成物(処方2:ハイドロキノン1重量%含有組成物)について試験例3と同様の評価を行った。その結果、室温保管の場合のみならず40℃保管の場合にも変色は認められず、引き続き保管を継続したところ、3ヶ月経過後も変色は認められなかった。
Claims (4)
- ハイドロキノンまたはその誘導体をリオトロピック液晶に配合してなることを特徴とする皮膚外用組成物。
- 請求項1記載の皮膚外用組成物からなることを特徴とする美白化粧料。
- 請求項1記載の皮膚外用組成物とレチノイドを含有する皮膚外用組成物が各別包装されてなり、両者が組み合わせて使用されることを特徴とする組み合わせ化粧料。
- レチノイドを含有する皮膚外用組成物がレチノイドを2価金属無機塩微粒子に封入された形態で含有することを特徴とする請求項3記載の組み合わせ化粧料。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/865,494 US20100330014A1 (en) | 2008-01-30 | 2009-01-29 | Composition for external application on skin, and skin-whitening cosmetic |
JP2009551575A JPWO2009096481A1 (ja) | 2008-01-30 | 2009-01-29 | 皮膚外用組成物および美白化粧料 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008019002 | 2008-01-30 | ||
JP2008-019002 | 2008-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009096481A1 true WO2009096481A1 (ja) | 2009-08-06 |
Family
ID=40912826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/051488 WO2009096481A1 (ja) | 2008-01-30 | 2009-01-29 | 皮膚外用組成物および美白化粧料 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100330014A1 (ja) |
JP (1) | JPWO2009096481A1 (ja) |
KR (1) | KR20100111311A (ja) |
WO (1) | WO2009096481A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ713342A (en) * | 2013-03-15 | 2020-12-18 | Laboratory Skin Care Inc | Fine dry particulate retinoid active agent compositions and topical formulations including the same |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61271204A (ja) * | 1985-05-27 | 1986-12-01 | Shiseido Co Ltd | リポソ−ム製剤 |
JPS62215513A (ja) * | 1985-12-11 | 1987-09-22 | エルヴェエムアッシュ・ルシェルシュ | レチノイドまたはカロチノイドを含む含水脂質ラメラ相からなる薬剤組成物 |
JPH07324029A (ja) * | 1993-12-30 | 1995-12-12 | L'oreal Sa | 皮膚の表面層と深層の同時処置のための脱色素沈着組成物およびその用途並びに皮膚の脱色素沈着方法 |
WO1998007406A1 (en) * | 1996-08-21 | 1998-02-26 | The Procter & Gamble Company | Skin lightening compositions |
JP2001240511A (ja) * | 2000-02-16 | 2001-09-04 | L'oreal Sa | N−コレステリルオキシカルボニル−4−パラ−アミノフェノールとヒドロキノンまたはその誘導体の一つとをベースとする組成物 |
JP2002121408A (ja) * | 2000-10-02 | 2002-04-23 | Consortium Elektrochem Ind Gmbh | 顔料複合体および層構造体 |
WO2006118245A1 (ja) * | 2005-04-28 | 2006-11-09 | Japan Science And Technology Agency | 皮膚再生促進剤 |
WO2007136067A1 (ja) * | 2006-05-23 | 2007-11-29 | Shiseido Company Ltd. | 皮膚外用剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108756A (en) * | 1989-01-12 | 1992-04-28 | Pfizer Inc. | Dispensing devices powered by lyotropic liquid crystals |
AU2003273010A1 (en) * | 2003-10-15 | 2005-05-05 | Ltt Bio-Pharma Co., Ltd. | Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt |
-
2009
- 2009-01-29 JP JP2009551575A patent/JPWO2009096481A1/ja not_active Withdrawn
- 2009-01-29 US US12/865,494 patent/US20100330014A1/en not_active Abandoned
- 2009-01-29 KR KR1020107019262A patent/KR20100111311A/ko not_active Application Discontinuation
- 2009-01-29 WO PCT/JP2009/051488 patent/WO2009096481A1/ja active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61271204A (ja) * | 1985-05-27 | 1986-12-01 | Shiseido Co Ltd | リポソ−ム製剤 |
JPS62215513A (ja) * | 1985-12-11 | 1987-09-22 | エルヴェエムアッシュ・ルシェルシュ | レチノイドまたはカロチノイドを含む含水脂質ラメラ相からなる薬剤組成物 |
JPH07324029A (ja) * | 1993-12-30 | 1995-12-12 | L'oreal Sa | 皮膚の表面層と深層の同時処置のための脱色素沈着組成物およびその用途並びに皮膚の脱色素沈着方法 |
WO1998007406A1 (en) * | 1996-08-21 | 1998-02-26 | The Procter & Gamble Company | Skin lightening compositions |
JP2001240511A (ja) * | 2000-02-16 | 2001-09-04 | L'oreal Sa | N−コレステリルオキシカルボニル−4−パラ−アミノフェノールとヒドロキノンまたはその誘導体の一つとをベースとする組成物 |
JP2002121408A (ja) * | 2000-10-02 | 2002-04-23 | Consortium Elektrochem Ind Gmbh | 顔料複合体および層構造体 |
WO2006118245A1 (ja) * | 2005-04-28 | 2006-11-09 | Japan Science And Technology Agency | 皮膚再生促進剤 |
WO2007136067A1 (ja) * | 2006-05-23 | 2007-11-29 | Shiseido Company Ltd. | 皮膚外用剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2009096481A1 (ja) | 2011-05-26 |
KR20100111311A (ko) | 2010-10-14 |
US20100330014A1 (en) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Raut et al. | Lecithin organogel: A unique micellar system for the delivery of bioactive agents in the treatment of skin aging | |
CA2943179C (en) | Compositions and methods for enhancing the topical application of an acidic benefit agent | |
ES2719575T3 (es) | Composiciones y métodos para mejorar la aplicación tópica de un agente beneficioso básico | |
JP5271538B2 (ja) | 皮膚再生促進剤 | |
ES2565317T3 (es) | Composición tópica para el cuidado de la piel | |
US20050048020A1 (en) | Novel topical delivery system for plant derived anti-irritants | |
JP7295809B2 (ja) | アスコルビン酸及び/又はその塩を含有する外用組成物 | |
JPWO2006118246A1 (ja) | 経皮吸収促進剤 | |
WO2011115034A1 (ja) | 液体口腔用組成物及びその製造方法 | |
KR20110036683A (ko) | 피부 치료용 벤조일 퍼옥사이드 조성물 | |
KR20180027375A (ko) | 식물 태지 성분을 포함하는 피부 보습용 화장료 조성물 | |
EP2617410B1 (en) | Oil-in-water type cosmetic | |
JP2023164933A (ja) | アスコルビン酸及び/又はその塩を含有する外用組成物 | |
KR101176523B1 (ko) | 성상 변화를 갖는 화장료 조성물 | |
JP7426536B1 (ja) | アスコルビン酸及び/又はその塩を含有する外用組成物 | |
JP2010229117A (ja) | 皮膚外用剤 | |
WO2009096481A1 (ja) | 皮膚外用組成物および美白化粧料 | |
JP6198279B2 (ja) | 新規組成物 | |
KR102086316B1 (ko) | 경피흡수성이 우수한 화장료 조성물 | |
JP2010001218A (ja) | 皮膚外用組成物および皮膚再生促進剤 | |
CN114828839A (zh) | 具有增强的稳定性的维生素a和维生素c组合 | |
JP2009179570A (ja) | 皮膚外用組成物および色素沈着抑制剤 | |
JP3806871B2 (ja) | 透明水性基剤 | |
JP5999903B2 (ja) | 液状化粧料 | |
JP2024007126A (ja) | 多層液状化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09705895 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009551575 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12865494 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20107019262 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09705895 Country of ref document: EP Kind code of ref document: A1 |